Evidence map›Paper›PMID 42548335›Full record

ReviewCHEST pulmonary2023

Primary Ciliary Dyskinesia.

Michael Glenn O'Connor, Ricardo Mosquera, Hilda Metjian, Meghan Marmor, Kenneth N Olivier, Adam J Shapiro

Abstract readReview
In one paragraph

Review in CHEST pulmonary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. CHEST pulmonary · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Advances in respiratory medicine · 2025
    Article
  8. Primary ciliary dyskinesia.Paediatrics & child health · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael Glenn O'ConnorDivision of Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Ricardo MosqueraDivision Pulmonary Medicine, Department of Pediatrics, McGovern Medical School at The University of Texas Health Science Center at Houston and Children's Memorial Hermann Hospital, Houston, TX.
Hilda MetjianDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO.
Meghan MarmorDivision of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA.
Kenneth N OlivierDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Adam J ShapiroDivision of Pediatric Respiratory Medicine, McGill University Health Centre Research Institute, Montreal, QC, Canada.

Funding

Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary DyskinesiaU54HL096458 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI OLIVIER, KENNETH N. · 2009 to 2023
$20.0M
NHLBI NIH HHS U54 HL096458
6 · The paper itself

Abstract

Primary ciliary dyskinesia (PCD) is a rare but underdiagnosed disorder that affects motile cilia function throughout the body. With increasing prevalence through ongoing genetic discovery, PCD underlies the disease process in a significant number of patients with chronic suppurative lung disease and bronchiectasis when properly investigated using current diagnostic standards. Classic PCD symptoms include chronic rhinosinusitis and otitis, organ laterality defects, infertility, year-round productive cough, and recurrent pneumonias with bronchiectasis. Clinical symptoms of PCD manifest very early in life (often at birth), although diagnosis frequently is delayed because of poor phenotypic recognition and limited access to specialized diagnostic testing. In the past decade, PCD research networks have established specific PCD phenotypes to increase clinical recognition, and the availability of PCD genetic panels in various commercial laboratories has expanded access to an accurate PCD diagnosis greatly. Clinical practice guidelines also were created to guide diagnosis and management of this rare but increasingly recognized suppurative respiratory disease. PCD is more common than previously thought and can be recognized through specific clinical phenotypes in both children and adults. Diagnostic PCD testing outside of highly specialized centers can be difficult, but increased availability of nasal nitric oxide measurement and commercial genetic panels now allows for noninvasive screening and definitive diagnosis regardless of center expertise. Identification of patients with accurately diagnosed PCD is needed worldwide to populate future clinical trials and to develop disease-specific therapies for PCD.

Indexed as

bronchiectasisKartagenerlateralityprimary ciliary dyskinesiasinusitis

Identifiers

PMID42548335
PMCPMC13417580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.